American Heart Journal
Volume 151, Issue 5 , Pages 949-955, May 2006

Management of elderly patients with congestive heart failure—Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

  • Hans Peter Brunner–La Rocca, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Peter Theo Buser, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Ruth Schindler, RN

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Alain Bernheim, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Peter Rickenbacher, MD

      Affiliations

    • Division of Cardiology, Kantonsspital Bruderholz, Bruderholz, Switzerland
  • ,
  • Matthias Pfisterer, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • Corresponding Author InformationReprint requests: Matthias Pfisterer, MD, FESC, FACC, FAHA, Head Division of Cardiology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland.
  • ,
  • for the TIME-CHF-Investigators

Received 7 July 2005; accepted 20 October 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study is sponsored by the Horten Foundation, Lugano, Switzerland, as well as by unrestricted grants from AstraZeneca Pharma, Menarini Pharma, Novartis Pharma, Pfizer Pharma, Servier (all Switzerland with equal contributions), Roche Diagnostics, Roche Pharma, and Merck Pharma, Switzerland.

PII: S0002-8703(05)01006-9

doi:10.1016/j.ahj.2005.10.022

American Heart Journal
Volume 151, Issue 5 , Pages 949-955, May 2006